NASDAQ:RLYB Rallybio Q3 2026 Earnings Results & Report $15.93 -0.72 (-4.32%) Closing price 10/27/2026 04:00 PM EasternExtended Trading$16.00 +0.06 (+0.41%) As of 10/27/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Rallybio beat analyst earnings expectations in its Q3 2026 results, released October 27, 2026. The company reported EPS of -$0.48 versus the -$1.44 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateOctober 27, 2026TimeBefore Market OpensConference Call7:00 AM ET Rallybio EPS ResultsActual EPS-$0.48Consensus EPS -$1.44Beat/MissBeat by +$0.96One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersRallybio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsRallybio's Q4 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedulesConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Rallybio Q3 2026 Earnings FAQ Did Rallybio beat earnings estimates for Q3 2026? Rallybio (NASDAQ:RLYB) reported earnings of -$0.48 per share for Q3 2026, beating the consensus estimate of -$1.44. The report was announced on Tuesday, October 27, 2026. When is Rallybio's next earnings date? Rallybio's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Rallybio on the company's earnings history page. Rallybio Earnings HeadlinesRallybio Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026October 27 at 9:03 PM | marketscreener.comMRallybio CFO Transition Amid Pending Avenzo Therapeutics MergerSeptember 9, 2026 | tipranks.comMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found. | Crypto 101 Media (Ad)Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYBJune 2, 2026 | businesswire.comRLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own?June 1, 2026 | finance.yahoo.comRLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its ShareholdersJune 1, 2026 | businesswire.comSee More Rallybio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Rallybio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rallybio and other key companies, straight to your email. Email Address About RallybioRallybio (NASDAQ:RLYB) is a clinical-stage biotechnology company focused on developing medicines for patients with rare diseases, with an emphasis on conditions that affect maternal and fetal health, as well as other serious disorders with limited treatment options. The company is headquartered in New Haven, Connecticut, and its programs are intended for specialized patient populations in the United States and international markets. Rallybio’s lead program, RLYB212, is being developed to prevent fetal and neonatal alloimmune thrombocytopenia, a rare condition in which maternal antibodies attack fetal platelets during pregnancy. The program is designed to target the HPA-1a antigen and potentially reduce the risk of severe bleeding and related complications in newborns. The company has also advanced programs involving complement biology, including RLYB116, an investigational complement inhibitor intended for potential use in diseases driven by inappropriate complement activation. Rallybio’s research and development strategy is centered on identifying significant unmet medical needs and advancing targeted therapies through clinical development and potential regulatory approval.View Rallybio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple's Foldable iPhone Sold Out in Minutes, But Wall Street Has QuestionsCoca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest StrengthWhirlpool's Stock Collapse Raises a Bigger Question About Its Recovery PotentialAnalysts Turn Bullish on Meta Platforms Despite Post-Earnings FallLockheed Martin's F-35 Deal Could Change How Wall Street Values the StockIntel's $155 Price Target Raises a Bigger Question About Its Turnaround PotentialMerck and Moderna's Cancer Vaccine Worked—Who Gets Paid? Upcoming Earnings Amazon.com (10/29/2026)Mondelez International (10/29/2026)Starbucks (10/29/2026)Cheniere Energy (10/29/2026)TotalEnergies (10/29/2026)BP (10/30/2026)Chevron (10/30/2026)AstraZeneca (10/30/2026)Sanofi (10/30/2026)Canadian National Railway (10/30/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
